Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $3.31 USD
Change Today -0.09 / -2.65%
Volume 534.3K
As of 8:10 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Robert L. Kirkman M.D.

Chief Executive Officer, President and Director,Oncothyreon Inc
AgeTotal Calculated CompensationThis person is connected to 13 board members in 2 different organizations across 4 different industries.

See Board Relationships
As of Fiscal Year 2014


Dr. Robert L. Kirkman, MD has been the Chief Executive Officer and President of Oncothyreon Inc. (alternate name Biomira Inc) since September 5, 2006. Dr. Kirkman served as an Acting President and Acting Chief Executive Officer at Xcyte Therapies Inc., from July 2005 to 2006. He served as Chief Business Officer and Vice President of Xcyte Therapies Inc., from February 16, 2004 to July 2005. He served as Chief Executive Officer of Xcyte Therapies Inc. He served as Chief ...

Read Full Background

Corporate Headquarters*

2601 Fourth Avenue
Seattle, Washington 98121

United States

Phone: 206-801-2100
Fax: 206-801-2101

Board Members Memberships*

Chief Executive Officer, President and Director
Independent Director, Member of Audit Committee and Member of Compensation Committee


Harvard Medical School
Yale University

Other Affiliations*

Annual Compensation*

Total Annual Compensation$435,000

Stock Options*

All Other Compensation$12,455
Exercisable Options857,537
Exercisable Options Value$104,000
Unexercisable Options825,000
Unexercisable Options Value$114,000
Total Value of Options$218,000
Total Number of Options1,682,537

Total Compensation*

Total Annual Cash Compensation$664,955
Total Short Term Compensation$435,000
Other Long Term Compensation$12,455
Total Calculated Compensation$1,024,955
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONTY:US $3.31 USD -0.09


There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOTHYREON INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at